Horien Biotech officially listed on the OTC market today at an underwriting price of NT$28.47. As of now, the stock has reached a high of NT$32.15, a 12.9% increase. Recently, it successfully obtained three high-risk, highest-level Class 4 medical device market licenses in Thailand, opening the door to high-end medical devices in Southeast Asia.

 Horien Biotech is expected to obtain Class III medical device licenses in the Philippines and Vietnam soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion. Its highly anticipated bio-ink innovative product is planned to be officially exported to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and is expected to see a surge in global revenue contributions.

 In the research and development of high-end innovative medical devices, Horien Biotech has achieved a disruptive world-class breakthrough. Its independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and will soon obtain invention patents in the United States, Europe, and China, targeting a multi-billion dollars blue ocean market.

 The innovative product has successfully completed sample development and has been officially delivered for animal testing. Since no other company in the industry has yet obtained the relevant medical device certification, Horien Biotechnology is at the forefront globally. This will not only solve the clinical pain point of traditional stents requiring secondary surgery for removal, but also allow them to access a vast, untapped market worth billions of dollars.

 To meet the explosive global demand and ensure a secure supply of high-end medical device raw materials, Horien Biotechnology's subsidiary, Shengli Biotechnology, has officially signed Memoranda of Understanding (MOUs) with Taiwan Sugar Corporation and Taiwan Livestock Corporation, adhering to ISO 13485 (Medical Device Quality Management System) and ISO 22442 (Risk Management of Medical Devices Using Animal Tissue), establishing a high-standard international supply chain for medical-grade animal-derived raw materials.

 Horien Biotech Chairman Tsai Kuo-Tien stated that Horien Biotech will continue to deepen its global market penetration based on its existing dental and surgical channels, leveraging top-tier medical-grade raw materials and groundbreaking high-end medical devices and drugs. With international certifications secured and innovative product lines entering their harvest period, Horien Biotech will achieve steady and rapid growth, creating maximum value for all shareholders and the Taiwanese biotech industry.

Report Link:

Horien Biotech's stock price surged on its first day of trading on the OTC market! It has gained access to ASEAN's high-end medical device market

TechNews / Yao Hui-Ru